- Trials with a EudraCT protocol (445)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
445 result(s) found for: Organs.
Displaying page 1 of 23.
EudraCT Number: 2011-001699-20 | Sponsor Protocol Number: 042011 | Start Date*: 2012-05-18 |
Sponsor Name:St. Anna Kinderkrebsforschung, GmbH | ||
Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS | ||
Medical condition: Langerhans cell histiocytosis | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001593-18 | Sponsor Protocol Number: 958 | Start Date*: 2015-06-02 |
Sponsor Name:Medizinische Universiät Wien | ||
Full Title: A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans | ||
Medical condition: Investigation in volunteers only | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005796-14 | Sponsor Protocol Number: 1/2013 | Start Date*: 2014-05-13 |
Sponsor Name:Medizinische Universität Wien | ||
Full Title: A randomized, pilot study to assess the impact of single nucleotide polymorphisms in the ABCB1 and ABCG2 genes on brain and organ distribution of dual Pgp/BCRP substrates in humans. | ||
Medical condition: The effect of genetic polymorphisms on drug distribution will be investigated in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-010982-22 | Sponsor Protocol Number: DSC/08/2357/38 | Start Date*: 2009-04-20 | |||||||||||
Sponsor Name:ITALFARMACO | |||||||||||||
Full Title: Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy | |||||||||||||
Medical condition: Polycythemia Vera | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023254-36 | Sponsor Protocol Number: GUMPID002 | Start Date*: 2011-06-22 | |||||||||||
Sponsor Name:Brighton and Sussex University Hospitals NHS Trust | |||||||||||||
Full Title: Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)? | |||||||||||||
Medical condition: Pelvic Inflammatory Disease (PID) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001602-24 | Sponsor Protocol Number: Th.B-1(2007):BTX(CP/CPPS) | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Department of Urology and Pediatric Urology - Justus-Liebig-University Giessen | |||||||||||||
Full Title: Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) | |||||||||||||
Medical condition: chronic prostatitis / chronic pelvic pain syndrom | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003845-41 | Sponsor Protocol Number: UCL/07/131 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Transplantation of umbilical cord blood (UCB) from unrelated donors (URD) in patients with haematological diseases using a reduced intensity conditioning regimen. | |||||||||||||
Medical condition: Haematological disorders | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024094-39 | Sponsor Protocol Number: Adip-2010 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Ulm, University Hospital Ulm | ||
Full Title: Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. | ||
Medical condition: The purpose of this study is to determine the free tissue kinetics of ertapenem and meropenem in fatty tissue and intraperitoneal fluid up to 24 hours after administration of the IMP. Subjects are ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001344-57 | Sponsor Protocol Number: PENTALLO | Start Date*: 2019-10-10 | |||||||||||
Sponsor Name:GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA | |||||||||||||
Full Title: Pentaglobin as early adjuvant treatment for febrile neutropenia in acute leukemia or allogeneic hematopoietic stem cell transplant patients colonized by carbapenem-resistant Enterobacteriaceae or P... | |||||||||||||
Medical condition: The study will enroll consecutive adult patients suffering from acute leukemia candidate to intensive chemotherapy or patients with hematological cancers candidate to allogeneic transplant with a d... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001841-11 | Sponsor Protocol Number: MPOH06 | Start Date*: 2021-11-09 | |||||||||||
Sponsor Name:MaaT Pharma | |||||||||||||
Full Title: Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial | |||||||||||||
Medical condition: Salvage therapy of acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005524-26 | Sponsor Protocol Number: GBI1406 | Start Date*: 2016-07-29 | |||||||||||
Sponsor Name:Grifols Biologicals Inc. | |||||||||||||
Full Title: A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIIIVWF Alphanate® in Immune Tolerance Induction Therapy in Subjects with Congenital Hemoph... | |||||||||||||
Medical condition: Inhibitors in patients with severe Congenital Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011818-21 | Sponsor Protocol Number: UCL/09/0128 | Start Date*: 2010-06-28 | |||||||||||
Sponsor Name:University College London [...] | |||||||||||||
Full Title: Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen | |||||||||||||
Medical condition: Haematological disorders | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003568-38 | Sponsor Protocol Number: LCH-IV-G-2016 | Start Date*: 2017-11-14 |
Sponsor Name:Johann Wolfgang Goethe-University Frankfurt am Main | ||
Full Title: German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV | ||
Medical condition: Langerhans cell Histiocytosis (LCH) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004886-33 | Sponsor Protocol Number: A06-269 | Start Date*: 2007-06-05 |
Sponsor Name:University of Athens, Medical school | ||
Full Title: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND IMMUNOMODULATORY THERAPY FOR THE MANAGEMENT OF SEPSIS | ||
Medical condition: septic syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004090-28 | Sponsor Protocol Number: Fx-R-001-S1/B3461049 | Start Date*: 2014-05-13 |
Sponsor Name:Fold RX Pharmaceuticals, a Pfizer Company | ||
Full Title: TRANSTHYRETIN-ASSOCIATED AMYLOIDOSES OUTCOMES SURVEY (THAOS) – OPTIONAL BLOOD SAMPLE COLLECTION SUBSTUDY | ||
Medical condition: Transthyretin (TTR) a 127-amino acid, tetrameric protein, primarily synthesized in the liver, is a secreted protein present in the blood and cerebrospinal fluid and is a carrier of thyroxine and r... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002222-23 | Sponsor Protocol Number: P170932J | Start Date*: 2019-02-05 |
Sponsor Name:APHP | ||
Full Title: Cobimetinib for BRAF-wild-type histiocytoses : a randomized, placebo-controlled, double blind study | ||
Medical condition: Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. patients with BRAF-wild type. | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003461-17 | Sponsor Protocol Number: 71272 | Start Date*: 2020-01-07 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF) | ||
Medical condition: Heart failure with preserved ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001306-30 | Sponsor Protocol Number: PROICM2021-04REL | Start Date*: 2021-09-13 | |||||||||||
Sponsor Name:Institut Régional du Cancer de Montpellier | |||||||||||||
Full Title: A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine ... | |||||||||||||
Medical condition: Patients with new progression of intestinal well-differentiated neuroendocrine tumor. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004727-37 | Sponsor Protocol Number: CAAA603A12101 | Start Date*: 2019-02-18 |
Sponsor Name:Advanced Accelerator Applications International SA | ||
Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with... | ||
Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) ES (Ongoing) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019017-25 | Sponsor Protocol Number: CSOM230CIC01T | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Freistaat Bayern, represented by Universität Regensburg | |||||||||||||
Full Title: Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size | |||||||||||||
Medical condition: Primary inoperable thymoma and/or local recurrent thymoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
